192 related articles for article (PubMed ID: 6751921)
1. Increased antitumor activity of Escherichia coli. L-asparaginase by modification with monomethoxypolyethylene glycol.
Kamisaki Y; Wada H; Yagura T; Nishimura H; Matsushima A; Inada Y
Gan; 1982 Jun; 73(3):470-4. PubMed ID: 6751921
[TBL] [Abstract][Full Text] [Related]
2. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.
Abuchowski A; Kazo GM; Verhoest CR; Van Es T; Kafkewitz D; Nucci ML; Viau AT; Davis FF
Cancer Biochem Biophys; 1984 Jun; 7(2):175-86. PubMed ID: 6467175
[TBL] [Abstract][Full Text] [Related]
3. Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol.
Kamisaki Y; Wada H; Yagura T; Matsushima A; Inada Y
J Pharmacol Exp Ther; 1981 Feb; 216(2):410-4. PubMed ID: 7007618
[TBL] [Abstract][Full Text] [Related]
4. Gel entrapped L-asparaginase: kinetic behavior and antitumor activity.
O'Driscoll KF; Korus RA; Ohnuma T; Walczack IM
J Pharmacol Exp Ther; 1975 Nov; 195(2):382-8. PubMed ID: 241845
[TBL] [Abstract][Full Text] [Related]
5. Improvement in the therapeutic, immunological, and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginases by attachment of poly-DL-alanyl peptides.
Uren JR; Ragin RC
Cancer Res; 1979 Jun; 39(6 Pt 1):1927-33. PubMed ID: 376113
[TBL] [Abstract][Full Text] [Related]
6. Chemical modification of L-asparaginase with comb-shaped copolymer of poly(ethylene glycol) derivative and maleic anhydride.
Saito T; Ueno T; Sekine T; Kodera Y; Hiroto M; Matsushima A; Nishimura H; Inada Y
Leukemia; 1997 Apr; 11 Suppl 3():408-9. PubMed ID: 9209407
[TBL] [Abstract][Full Text] [Related]
7. Immunological effects of native and polyethylene glycol-modified asparaginases from Vibrio succinogenes and Escherichia coli in normal and tumour-bearing mice.
Bendich A; Kafkewitz D; Abuchowski A; Davis FF
Clin Exp Immunol; 1982 Apr; 48(1):273-8. PubMed ID: 7044632
[TBL] [Abstract][Full Text] [Related]
8. [Preparation of repeatedly and effectively usable L-asparaginase by a chemical modification].
Nishimura H; Wada H; Inada Y
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2227-35. PubMed ID: 6548355
[TBL] [Abstract][Full Text] [Related]
9. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
Yoshimoto T; Nishimura H; Saito Y; Sakurai K; Kamisaki Y; Wada H; Sako M; Tsujino G; Inada Y
Jpn J Cancer Res; 1986 Dec; 77(12):1264-70. PubMed ID: 3102431
[TBL] [Abstract][Full Text] [Related]
10. A review of the preclinical antitumor activity and toxicology of L-asparaginase derived from E. coli.
Charles LM; Bono VH
Cancer Treat Rep; 1981; 65 Suppl 4():39-46. PubMed ID: 7049380
[No Abstract] [Full Text] [Related]
11. Basis for loss of therapeutic effectiveness of L-asparaginase in sensitized mice.
Baechtel S; Prager MD
Cancer Res; 1973 Aug; 33(8):1966-9. PubMed ID: 4578567
[No Abstract] [Full Text] [Related]
12. The chemical modification of E. coli L-asparaginase by N,O-carboxymethyl chitosan.
Qian G; Zhou J; Ma J; Wang D; He B
Artif Cells Blood Substit Immobil Biotechnol; 1996 Nov; 24(6):567-77. PubMed ID: 8922226
[TBL] [Abstract][Full Text] [Related]
13. [Results of an experimental study of the antitumor activity of 1-asparaginase from E. coli and Erw. carotovora].
Terent'eva TG; Sokolov AB; Navashin SM
Antibiotiki; 1977 Jan; 22(1):78-81. PubMed ID: 320935
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases.
Roberts J; Schmid FA; Old LJ; Stockert E
Cancer Biochem Biophys; 1976 May; 1(4):175-8. PubMed ID: 788892
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of lymphoma 6C3HED by L-asparaginase from Serratia marcescens.
Boyd JW; Phillips AW
J Natl Cancer Inst; 1971 Jun; 46(6):1271-6. PubMed ID: 4932428
[No Abstract] [Full Text] [Related]
16. Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct.
Park YK; Abuchowski A; Davis S; Davis F
Anticancer Res; 1981; 1(6):373-6. PubMed ID: 7046623
[TBL] [Abstract][Full Text] [Related]
17. Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase.
Abuchowski A; van Es T; Palczuk NC; McCoy JR; Davis FF
Cancer Treat Rep; 1979 Jun; 63(6):1127-32. PubMed ID: 466651
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of polyethylene glycol-L-asparaginase.
Ho DH; Brown NS; Yen A; Holmes R; Keating M; Abuchowski A; Newman RA; Krakoff IH
Drug Metab Dispos; 1986; 14(3):349-52. PubMed ID: 2872037
[TBL] [Abstract][Full Text] [Related]
19. L-Asparaginase: discovery and development as a tumor-inhibitory agent.
Broome JD
Cancer Treat Rep; 1981; 65 Suppl 4():111-4. PubMed ID: 7049374
[No Abstract] [Full Text] [Related]
20. Clinical evaluation of L-asparaginase. Introduction.
Burchenal JH; Karnofsky DA
Cancer; 1970 Feb; 25(2):241-3. PubMed ID: 4905151
[No Abstract] [Full Text] [Related]
[Next] [New Search]
